The Longevity Reality Radar
46 approaches, rated by evidence.

Urolithin A (Mitopure)

Urolithin A (mitophagy activator). Aging itself. Reviewed Jul 2026.

Randomised trials show modest gains in muscle strength, endurance and immune markers, but there is no lifespan or disease-outcome data.

Stage
Human biomarker trials
Rung: Early human signal. First human or biomarker data. Promising, unproven.
Evidence grade
B
RCTs, function markers
Randomised human data on surrogate markers, or consistent large cohorts. How grades work.

What it is

A postbiotic — the gut metabolite of ellagitannins (pomegranate, walnuts) — sold as Mitopure. It switches on mitophagy, the cellular cleanup that clears damaged mitochondria before they sap energy, muscle and immune function.

The evidence

Randomized human trials at 1,000 mg/day: improved muscle strength and endurance in older adults, lowered markers of cellular senescence, and raised CD8+ T cells and natural killer cells (markers of immune aging); one study reported ~10% greater VO2max gain than exercise alone. Available over-the-counter; no hard lifespan or disease-outcome data yet.

What you can do today

The human evidence is early and does not support a general recommendation. If this area is relevant to you, discuss it with a clinician. Products sold in this space are not proof that it works.

Sources

  • Coverage, not a sourcex.com

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Aging itself

All 17 in Aging itself.

  • Rapamycin for longevityGrade C, strong animal data. Approved drug, off-label use.Extends lifespan across many animal species, but there is no human outcome data for longevity and side effects such as poor wound healing and infection are real.
  • Acarbose for longevityGrade C, strong animal data. Approved drug, off-label use.One of the most reproducible lifespan extenders in mice, mainly in males, but there is no human longevity trial.
  • VO₂max and strength for longevityGrade B, large cohorts. Established.In large observational cohorts the top VO₂max quartile has about 4 to 5 times lower all-cause mortality than the bottom, and nothing pharmacological on this list comes close.
  • RentosertibGrade C, post-hoc biomarker. Phase 3, for lung fibrosis.Six aging clocks moved in 42 lung-fibrosis patients over 12 weeks, a design that cannot separate slowed aging from a treated lung, and no healthy-volunteer or outcome data exist.
  • Senolytics (dasatinib, quercetin, fisetin)Grade C, small human studies. Phase 1/2.Small human studies show the drugs can be given, with off-target side effects, but no durable benefit in people has been shown.
  • Partial epigenetic reprogramming (ER-100)Grade D, animal data only. Phase 1, in the eye.A first-in-human safety trial in the eye has started, but every efficacy result so far comes from animals.

Guides that cover this